North America Actinic Keratosis Treatment Market

North America Actinic Keratosis Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class, By Therapy (Surgery, Topical and Photodynamic Therapy), By End-use (Hospitals, Private Clinics, Homecare and Others), By Country and Growth Forecast, 2022 - 2028

Report Id: KBV-12190 Publication Date: November-2022 Number of Pages: 78
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Actinic Keratosis Treatment Market, by Drug Class
1.4.2 North America Actinic Keratosis Treatment Market, by Therapy
1.4.3 North America Actinic Keratosis Treatment Market, by End-use
1.4.4 North America Actinic Keratosis Treatment Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. North America Actinic Keratosis Treatment Market by Drug Class
3.1 North America Nucleoside Metabolic Inhibitor Market by Country
3.2 North America NSAIDs Market by Country
3.3 North America Immune Response Modifiers Market by Country
3.4 North America Photoenhancers Market by Country
3.5 North America Others Market by Country

Chapter 4. North America Actinic Keratosis Treatment Market by Therapy
4.1 North America Surgery Market by Country
4.2 North America Topical Market by Country
4.3 North America Photodynamic Therapy Market by Country

Chapter 5. North America Actinic Keratosis Treatment Market by End-use
5.1 North America Hospitals Market by Country
5.2 North America Private Clinics Market by Country
5.3 North America Homecare Market by Country
5.4 North America Others Market by Country

Chapter 6. North America Actinic Keratosis Treatment Market by Country
6.1 US Actinic Keratosis Treatment Market
6.1.1 US Actinic Keratosis Treatment Market by Drug Class
6.1.2 US Actinic Keratosis Treatment Market by Therapy
6.1.3 US Actinic Keratosis Treatment Market by End-use
6.2 Canada Actinic Keratosis Treatment Market
6.2.1 Canada Actinic Keratosis Treatment Market by Drug Class
6.2.2 Canada Actinic Keratosis Treatment Market by Therapy
6.2.3 Canada Actinic Keratosis Treatment Market by End-use
6.3 Mexico Actinic Keratosis Treatment Market
6.3.1 Mexico Actinic Keratosis Treatment Market by Drug Class
6.3.2 Mexico Actinic Keratosis Treatment Market by Therapy
6.3.3 Mexico Actinic Keratosis Treatment Market by End-use
6.4 Rest of North America Actinic Keratosis Treatment Market
6.4.1 Rest of North America Actinic Keratosis Treatment Market by Drug Class
6.4.2 Rest of North America Actinic Keratosis Treatment Market by Therapy
6.4.3 Rest of North America Actinic Keratosis Treatment Market by End-use

Chapter 7. Company Profiles
7.1 Almirall, S.A
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.1.5.2 Product Launches and Product Expansions:
7.2 LEO Pharma A/S
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 Biofrontera AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Research & Development Expenses
7.4 Sun Pharmaceuticals Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.5 3M Company
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 SWOT Analysis
7.6 Bausch Health Companies, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Novartis AG
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Viatris, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Galderma S.A.
7.9.1 Company Overview
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo